Endo received good news this week in a lawsuit alleging wrongdoing in how it marketed its testosterone drug Testim.
As the number of pending talc cases continues to tick upward, Johnson & Johnson is maintaining its defensive winning streak.
Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.
Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.
Call it a big day for Roche at the FDA, as the drug giant picked up two critical approvals on Thursday.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.
In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.
New discount deals with cost watchdogs in England have breast cancer drugs from Pfizer and Novartis on more equal footing than in the U.S.
B. Braun, one of three main saline suppliers, is closing a plant for maintenance, a move it acknowledges will make a bad supply situation worse.